Advertisement

International Journal of Clinical Pharmacy

, Volume 39, Issue 4, pp 874–880 | Cite as

Opioid analgesic use in Australia and The Netherlands: a cross-country comparison

  • Francisca N. Wagemaakers
  • Samantha A. Hollingworth
  • Sanne Kreijkamp-Kaspers
  • Ernest H. L. Tee
  • Anne J. Leendertse
  • Mieke L. van DrielEmail author
Research Article

Abstract

Background Increasing use of opioid analgesics (OA) has been reported worldwide. Objective To compare the use of OA in two countries in order to better understand these trends. Setting Outpatient settings in Australia and The Netherlands. Method We analysed publicly available government data on outpatient OA dispensing over 15 years (2000–2014). We compared dispensing trends for specific OA and explored medical (national clinical guidelines), contextual and policy-related factors to explain differences in use between the two countries. Main outcome measure OA prescribing in Australia and The Netherlands, absolute volume of use, preferred types of opioids and changes over time. Results The average annual increase in OA prescribing was 10% in Australia and 8% in The Netherlands between 2000 and 2014. In 2014, the total use of OA was 10.0 daily defined doses (DDD)/1000 population/day in Australia and 9.4 DDD/1000 population/day in The Netherlands. In Australia, the most commonly prescribed opioids were oxycodone and tramadol, compared to fentanyl and tramadol in The Netherlands. We found differences in prescribing guidelines, culture of prescribing and regulatory frameworks that could explain some of the observed differences. Conclusion OA prescribing has increased remarkably in both countries between 2000 and 2014 but the types of prescribed OA vary. Differences in national evidence-based guidelines influenced the types of OA used. Prescribing culture as well as regulatory policies and costs, may also contribute to the different patterns of OA use.

Keywords

Analgesic Australia Guidelines Opioids Pain Pharmacoepidemiology Prescribing The Netherlands 

Notes

Acknowledgements

We thank the Australian Government Department of Health and the Dutch National Health Care Institute for providing freely accessible data on medicine dispensing.

Funding

Francisca Wagemaakers was granted a UMC Utrecht Internationalization Committee Grant for strategic network development.

Conflicts of interest

All authors declare that they have no conflict of interest.

Supplementary material

11096_2017_492_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 18 kb)

References

  1. 1.
    Hollingworth SA, Gray PD, Hall WD, Najman JM. Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiol Drug Saf. 2015;24:628–36.CrossRefPubMedGoogle Scholar
  2. 2.
    Zin CS, Chen LC, Knaggs RD. Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain. 2014;18:1343–51.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Leong M, Murnion B, Haber PS. Examination of opioid prescribing in Australia from 1992 to 2007. Int Med J. 2009;39:676–81.CrossRefGoogle Scholar
  4. 4.
    Ruscitto A, Smith BH, Guthrie B. Changes in opioid and other analgesic use 1995–2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain. 2015;19:59–66.CrossRefPubMedGoogle Scholar
  5. 5.
    Hamunen K, Paakkari P, Kalso E. Trends in opioid consumption in the Nordic countries 2002–2006. Eur J Pain. 2009;13:954–62.CrossRefPubMedGoogle Scholar
  6. 6.
    Henschke N, Kamper SJ, Maher CG. The epidemiology and economic consequences of pain. Mayo Clin Proc. 2015;90:139–47.CrossRefPubMedGoogle Scholar
  7. 7.
    Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276–86.CrossRefPubMedGoogle Scholar
  8. 8.
    McCrorie C, Closs SJ, House A, Petty D, Ziegler L, Glidewell L, et al. Understanding long-term opioid prescribing for non-cancer pain in primary care: a qualitative study. BMC Fam Pract. 2015;16:121.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Peppin JF, Cheatle MD, Kirsh KL, McCarberg BH. The complexity model: a novel approach to improve chronic pain care. Pain Med. 2015;16:653–66.CrossRefPubMedGoogle Scholar
  10. 10.
    Roxburgh A, Bruno R, Larance B, Burns L. Prescription of opioid analgesics and related harms in Australia. Med J Aust. 2011;195:280–4.CrossRefPubMedGoogle Scholar
  11. 11.
    Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010. doi: 10.1002/14651858.CD006605.pub2.PubMedGoogle Scholar
  12. 12.
    Nicholas R, Roche A, Dobbin M, Lee N. Beyond the paper trail: using technology to reduce escalating harms from opioid prescribing in Australia. Aust N Z J Public Health. 2013;37:139–47.CrossRefPubMedGoogle Scholar
  13. 13.
    Australian Statistics on Medicines. Australian Government, Department of Health. https://www.pbs.gov.au/info/browse/statistics#ASM. Accessed 18 April 2017.
  14. 14.
    GIP databank. Genees- en hulpmiddelen Project [Drug Information Project]. Zorginstituut Nederland, Diemen. http://www.gipdatabank.nl/. Accessed 18 April 2017.
  15. 15.
    WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2015. www.whocc.no/atcddd. Accessed 18 April 2017.
  16. 16.
    Medicare Australia. Pharmaceutical benefits schedule item reports. http://medicarestatistics.humanservices.gov.au/statistics/pbs_item.jsp. Accessed 18 April 2017.
  17. 17.
    GIP databank. Genees- en hulpmiddelen Informatie Project [Drug Information Project]. Aantal DDD's per gebruiker 2000–2014 voor ATC-subgroep N02A: Opioiden [DDDs per user 2000–2014 for ATC subgroup N02A: Opioids]. Zorginstituut Nederland, Diemen. www.gipdatabank.nl/database.asp. Accessed 18 April 2017.
  18. 18.
    Moulds R, Briscoe P, Foreman L, Halliwell R, Hopper I, Johnstone J, et al. Therapeutic guidelines: analgesic. 2012, Version 6. Therapeutic Guidelines Limited. www.tg.org.au. Accessed 18 April 2017.
  19. 19.
    de Jong L, Janssen PGH, Keizer D, Köke AJA, Schiere S, van Bommel M, et al. NHG-Standaard Pijn: Nederlands Huisartsen Genootschap 2015 [NHG Guideline Pain: Dutch College of General Practitioners 2015]. https://www.nhg.org/standaarden/volledig/nhg-standaard-pijn. Accessed 18 April 2017.
  20. 20.
    Verduijn MM, Folmer H. Farmacotherapeutische Richtlijn Pijnbestrijding [Pharmacotherapeutic Guideline Analgesic]. Nederlands Huisartsen Genootschap 2007. https://www.henw.org/archief/volledig/id918-ftr-pijnbestrijding.html. Accessed 18 April 2017.
  21. 21.
    Garbe E, Jobski K, Schmid U. Utilisation of transdermal fentanyl in Germany from 2004 to 2006. Pharmacoepidemiol Drug Saf. 2012;21:191–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Kenan K, Mack K, Paulozzi L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000–2010. Open Med. 2012;6(2):e41–7.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Harrison CM, Charles J, Henderson J, Britt H. Opioid prescribing in Australian general practice. Med J Aust. 2012;196:380–1.CrossRefPubMedGoogle Scholar
  24. 24.
    Hollingworth SA, Symons M, Khatun M, Loveday B, Ballantyne S, Hall WD, et al. Prescribing databases can be used to monitor trends in opioid analgesic prescribing in Australia. Aust N Z J Public Health. 2013;37:132–8.CrossRefPubMedGoogle Scholar
  25. 25.
    Svendsen K, Borchgrevink P, Fredheim O, Hamunen K, Mellbye A, Dale O. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat Med. 2011;25:725–32.CrossRefPubMedGoogle Scholar
  26. 26.
    Nielsen S, Degenhardt L, Hoban B, Gisev N. Comparing opioids: a guide to estimating oral morphine equivalents (OME) in research. NDARC Technical Report No. 329. Sydney: National Drug and Alcohol Research Centre; 2014.Google Scholar
  27. 27.
    Roxburgh A, Hall WD, Burns L, Pilgrim J, Saar E, Nielsen S, Degenhardt L. Trends and characteristics of accidental and intentional codeine overdose deaths in Australia. Med J Aust. 2015;203:2991–7.CrossRefGoogle Scholar
  28. 28.
    De Maeseneer JM, van Driel ML, Green LA, van Weel C. The need for research in primary care. Lancet. 2003;362(9392):1314–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Holliday S, Magin P, Dunbabin J, Oldmeadow C, Lintzeris N, Attia J, et al. An evaluation of the prescription of opioids for chronic nonmalignant pain by Australian General Practitioners. Pain Med. 2013;14:62–74.CrossRefPubMedGoogle Scholar
  30. 30.
    Mossialos E, Wenzl M, Osborn R, Anderson C. International Profiles of Health Care Systems, 2014: Australia, Canada, Denmark, England, France, Germany, Italy, Japan, The Netherlands, New Zealand, Norway, Singapore, Sweden, Switzerland, and the United States. The Commonwealth Fund, January 2015. http://www.commonwealthfund.org/publications/fund-reports/2015/jan/international-profiles-2014. Accessed 18 April 2017.
  31. 31.
    van Ginneken E. Perennial health care reform—the long Dutch quest for cost control and quality improvement. N Engl J Med. 2015;373:885–9.CrossRefGoogle Scholar
  32. 32.
    Gauld N, Bryant L, Emmerton L, Kelly F, Kurosawa N, Buetow S. Why does increasing public access to medicines differ between countries? Qualitative comparison of nine countries. J Health Serv Res Policy. 2015;20:231–9.CrossRefPubMedGoogle Scholar
  33. 33.
    Seamark D, Seamark C, Greaves C, Blake S. GPs prescribing of strong opioid drugs for patients with chronic non-cancer pain: a qualitative study. Br J Gen Pract. 2013;63(617):821–8.CrossRefGoogle Scholar
  34. 34.
    Hutchinson K, Moreland AM, de Williams AC, Weinman J, Horne R. Exploring beliefs and practice of opioid prescribing for persistent non-cancer pain by general practitioners. Eur J Pain. 2007;11:93–8.CrossRefPubMedGoogle Scholar
  35. 35.
    McKinlay JB, Trachtenberg F, Marceau LD, Katz JN, Fischer MA. Effects of patient medication requests on physician prescribing behavior: results of a factorial experiment. Med Care. 2014;52:294–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Green DJ, Bedson J, Blagojevic-Burwell M, Jordan KP, van der Windt D. Factors associated with primary care prescription of opioids for joint pain. Eur J Pain. 2013;17:234–44.CrossRefPubMedGoogle Scholar
  37. 37.
    Campbell G, Nielsen S, Larance B, Bruno R, Mattick R, Hall W, et al. Pharmaceutical opioid use and dependence among people living with chronic pain: associations observed within the pain and opioids in treatment (POINT) cohort. Pain Med. 2015;16:1745–58.CrossRefPubMedGoogle Scholar
  38. 38.
    Burgess DJ, Crowley-Matoka M, Phelan S, Dovidio JF, Kerns R, Roth C, et al. Patient race and physicians’ decisions to prescribe opioids for chronic low back pain. Soc Sci Med. 2008;67:1852–60.CrossRefPubMedGoogle Scholar
  39. 39.
    Anderson KO, Green CR, Payne R. Racial and ethnic disparities in pain: causes and consequences of unequal care. J Pain. 2009;10:1187–204.CrossRefPubMedGoogle Scholar
  40. 40.
    Holliday S, Morgan S, Tapley A, Dunlop A, Henderson K, van Driel M, et al. The pattern of opioid management by Australian general practice trainees. Pain Med. 2015;16:1720–31.CrossRefPubMedGoogle Scholar
  41. 41.
    Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren S. Medication adherence in patients with chronic non-malignant pain: is there a problem? Eur J Pain. 2009;13:115–23.CrossRefPubMedGoogle Scholar
  42. 42.
    Rosser BA, McCracken LM, Velleman SC, Boichat C, Eccleston C. Concerns about medication and medication adherence in patients with chronic pain recruited from general practice. Pain. 2011;152:1201–5.CrossRefPubMedGoogle Scholar
  43. 43.
    McCracken LM, Hoskins J, Eccleston C. Concerns about medication and medication use in chronic pain. J Pain. 2006;7:726–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Hall J. Australian Health Care—the challenge of reform in a fragmented system. N Engl J Med. 2015;373:493–7.CrossRefPubMedGoogle Scholar
  45. 45.
    Breekveldt-Postma NS, Penning-van Beest FJ, Herings RM. Utilisation pattern of fentanyl transdermal system in The Netherlands. Pharmacoepidemiol Drug Saf. 2005;14:129–34.CrossRefPubMedGoogle Scholar
  46. 46.
    Medicijnkosten [Costs of medicines]. Zorginstituut Nederland, Diemen. http://www.medicijnkosten.nl/. Accessed 18 April 2017.
  47. 47.
    Pharmaceutical Benefits Scheme. Australian Government Department of Health. http://www.pbs.gov.au/browse/body-system?depth=2&codes=n02 Accessed 18 April 2017.
  48. 48.
    Jammal W, Gown G. Opioid prescribing pitfalls: medicolegal and regulatory issues. Aust Prescr. 2015;38:198–203.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Hobbs T, Baggoley C, Aloizos J, Anns M, Ballantyne S, Bevan V, et al. Opioids roundtable outcomes statement. Canberra: Australian Government Department of Health; 2015.Google Scholar
  50. 50.
    KNMG. Richtlijn Elektronisch voorschrijven [Guideline Electronic Prescribing]. Utrecht: Koninklijke Nederlandsche Maatschappij tot bevordering der Geneeskunst; 2013.Google Scholar

Copyright information

© Springer International Publishing 2017

Authors and Affiliations

  • Francisca N. Wagemaakers
    • 1
  • Samantha A. Hollingworth
    • 2
  • Sanne Kreijkamp-Kaspers
    • 3
  • Ernest H. L. Tee
    • 3
  • Anne J. Leendertse
    • 1
  • Mieke L. van Driel
    • 3
    Email author
  1. 1.Julius Center for Health Sciences and Primary CareUniversity Medical Center UtrechtUtrechtThe Netherlands
  2. 2.School PharmacyUniversity of QueenslandBrisbaneAustralia
  3. 3.Primary Care Clinical Unit, Faculty of MedicineUniversity of QueenslandBrisbaneAustralia

Personalised recommendations